Hexiang Wang

This inventor holds 18 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Beigene, Ltd., Beone Medicines | Gmbh, Beone Medicines I Gmbh. Active years: 2016-2026.

USPTO Granted Patents = 18 (Patent Applications = 9)

% Patents Active = 88.9

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 7 (Patent Applications = 16)

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 153(Granted Patents)

Company Filing History:

Beone Medicines | Gmbh

patents

1 out of 13

Beone Medicines I Gmbh

Years Active: 2016-2026

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735423 - (R) and (S)-3-(tert-butyl)-N-(1-(4-(6-(6-(4-((1-(4-(2,4-dioxotetrahydropyrimidin-1(2H)-YL)phenyl)piperidin-4-YL)methyl)piperazin-1-YL)pyridin-3-YL)-7H-pyrrolo[2,3-d]pyrimidin-4-YL)-2-methylphenyl)ethyl)-1,2,4-oxadiazole-5-carboxamide as bruton's tyrosine kinase (BTK) degraders (2026-09-15),

2. 12729203 - Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use (2026-09-08),

3. 12521440 - Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use (2026-01-13),

4. 11950763 - Self-propelled soft robot body (2024-04-09),

5. 11472788 - Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases (2022-10-18),

6. 11202782 - Treatment cancers using a combination comprising PARP inhibitors (2021-12-21),

7. 10899763 - Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof (2021-01-26),

8. 10882856 - 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases (2021-01-05),

9. 10647714 - 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases (2020-05-12),

10. 10501467 - Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors (2019-12-10),

11. 10457680 - Process for preparing a PARP inhibitor, crystalline forms, and uses thereof (2019-10-29),

12. 10280163 - 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases (2019-05-07),

13. 10112952 - Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors (2018-10-30),

14. 9827226 - Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones (2017-11-28),

15. 9617273 - Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors (2017-04-11),

Title: The Innovative Journey of Inventor Hexiang Wang

Introduction: Hexiang Wang is a pioneering inventor based in Beijing, China, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Hexiang Wang holds several patents in the areas of artificial intelligence, robotics, and renewable energy technologies, showcasing his continuous dedication to pushing the boundaries of technological advancement.

Career Highlights: With a career spanning over two decades, Hexiang Wang has worked with leading tech companies and research institutions, playing a key role in developing cutting-edge solutions that have revolutionized various industries.

Collaborations: Throughout his career, Hexiang Wang has collaborated with top researchers, engineers, and scientists from around the world, fostering a culture of innovation and knowledge sharing to drive progress in the field of technology.

Conclusion: Hexiang Wang's relentless pursuit of innovation and his passion for creating solutions that make a difference have solidified his reputation as a visionary inventor at the forefront of technological advancement.